Scotland’s rich culinary heritage ​is vital for the country’s economy – but it needs to be future-proofed, writes Dr Liz ...

Large mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...

The biotech segment, in particular, remains a source of concern due to limited visibility on future bookings and the potential impact of broader funding weaknesses in the sector. The prolonged ...

The biotech segment, in particular, remains a source of concern due to limited visibility on future bookings and the potential impact of broader funding weaknesses in the sector. The prolonged sales ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I was a bit worried last week’s ...

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...